نتایج جستجو برای: every week

تعداد نتایج: 344413  

Journal: :British Journal of Psychiatry 2000

Journal: :The Iowa Review 2007

Journal: :Third Text 1998

Journal: :The Iowa Review 1974

2014
Tsutomu Takeuchi Hisashi Yamanaka Naoki Ishiguro Nobuyuki Miyasaka Masaya Mukai Tsukasa Matsubara Shoji Uchida Hideto Akama Hartmut Kupper Vipin Arora Yoshiya Tanaka

OBJECTIVES To evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics. METHODS This randomised, double-blind, placebo-controlled, multicentre study evaluated adalimumab 40 mg every other week+MTX 6-8 mg every week versus MTX 6-8 mg every week alone for 26 weeks in patients with...

2015
Sebastian JCMM Neggers Vyacheslav Pronin Inga Balcere Moon-Kyu Lee Liudmila Rozhinskaya Marcello D Bronstein Mônica R Gadelha Pascal Maisonobe Caroline Sert Aart Jan van der Lely

OBJECTIVE To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg. DESIGN AND METHODS Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥ 6 months and had normal IGF1 levels. Lanreotide Autogel 120 mg was administered every 6 weeks for 24 weeks (phase ...

2017
Josef S Smolen Sandeep K Agarwal Elena Ilivanova Xie Lillian Xu Ye Miao Yanli Zhuang Ivo Nnane Waldemar Radziszewski Andrew Greenspan Anna Beutler Daniel Baker

OBJECTIVE Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despite methotrexate (MTX) therapy. METHODS Patients were randomly assigned (1:1:1:1:1) to receive pl...

2017
L. Cai J. Gu J. Zheng M. Zheng G. Wang L.‐Y. Xi F. Hao X.‐M. Liu Q.‐N. Sun Y. Wang W. Lai H. Fang Y.‐T. Tu Q. Sun J. Chen X.‐H. Gao Y. Gu H.D. Teixeira J.‐Z. Zhang M.M. Okun

BACKGROUND This phase 3 trial is the first to evaluate the efficacy and safety of treatment with the systemic TNF-α inhibitor, adalimumab, for Chinese patients with moderate-to-severe plaque psoriasis. METHODS In the 12-week, double-blind, placebo-controlled Period A, patients were randomized 4 : 1 to receive adalimumab 40 mg every-other-week (following a single 80 mg dose), or placebo every-...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید